



NDA 50-445/S-028

**SUPPLEMENT APPROVAL**

Triax Pharmaceuticals, Inc.  
Attention: Kathryn Bishburg, Pharm.D.  
Executive Director, Regulatory Affairs  
20 Commerce Drive, Suite 232  
Cranford, NJ 07016

Dear Dr. Bishburg:

Please refer to your Supplemental New Drug Application (sNDA) dated August 17, 2010, received August 19, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Minocin (minocycline hydrochloride) Oral Suspension.

We acknowledge your amendment dated August 31, 2010.

This supplement was submitted in response to an Agency supplement request letter dated June 17, 2010.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling text for package insert and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

## **LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to CDERMedWatchSafetyAlerts@fda.hhs.gov, and to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Deputy Director for Safety  
Division of Anti-Infective and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Application  
Type/Number

Submission  
Type/Number

Submitter Name

Product Name

-----  
NDA-50445

-----  
SUPPL-28

-----  
TRIAX  
PHARMACEUTICA  
LS LLC

-----  
MINOCIN

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR

09/14/2010